The structures of a novel investigative anticancer agent 1-bromoacetyl-3,3-dinitro azetidine (ABDNAZ, 2) and its synthetic precursor 1-tert-butyl-3-hydroxymethyl-3-nitroazetidine (1) were determined by single crystal X-ray diffraction. The data show that the chemical transformation from 1 to 2 resulted in an increase in crystal density of 0.725 Mg/m3 (1 = 1.232 Mg/m3; 2 = 1.957 Mg/m3). The azetidine ring of 1 is puckered while 2 is planar, consistent with sp2 hybridization of the ring nitrogen following conversion of the tertiary amine to an amide. The structural information will aid in elucidating the biological activity of 2. Single crystal X-ray diffraction studies revealed that conversion of 1-tert-butyl-3-hydroxymethyl-3-nitroazetidine to 1-bromoacetyl-3,3-dinitroazetidine results inflattening of the azetidine ring due to sp2 hybridization of the ring nitrogen, and a crystal density increase of 0.725 Mg/m3 (1.232 vs. 1.957 Mg/m3 respectively) is observed.
新型抗癌药物1-
溴乙酰基-3,3-二硝基氮杂
环丁烷(ABDNAZ,2)及其合成前体1-叔丁基-3-羟甲基-
3-硝基氮杂
环丁烷(1)的结构通过单晶X射线衍射测定。数据显示,从1到2的
化学转化导致晶体密度增加0.725 Mg/m3(1 = 1.232 Mg/m3;2 = 1.957 Mg/m3)。1的氮杂
环丁烷环是褶皱的,而2是平面的,这与三级胺转化为酰胺后环氮的sp2杂化一致。结构信息将有助于阐明2的
生物活性。单晶X射线衍射研究表明,1-叔丁基-3-羟甲基-
3-硝基氮杂
环丁烷转化为1-
溴乙酰基-3,3-二硝基氮杂
环丁烷会导致氮杂
环丁烷环变平,这是由于环氮的sp2杂化,并且观察到晶体密度增加0.725 Mg/m3(分别为1.232和1.957 Mg/m3)。